For manufacturers involved in the production of essential pharmaceuticals, sourcing high-quality intermediates is a critical step. NINGBO INNO PHARMCHEM CO.,LTD. specializes in providing key building blocks, including Potassium N-Propylsulfamide (CAS 1393813-41-6). This compound is a vital Macitentan intermediate, essential for the synthesis of a medication that treats pulmonary arterial hypertension (PAH), a severe and progressive disease.

The Macitentan synthesis pathway relies on the consistent quality and availability of its precursors. Potassium N-Propylsulfamide, presented as a white to off-white powder, offers a reliable assay of u226598.0%, ensuring that the subsequent reactions proceed efficiently and yield a high-purity final product. The chemical name, Propylsulfamide potassium salt, also refers to this crucial compound. Its molecular formula is C3H11N2O2S.K, with a molecular weight of 178.3. Understanding these fundamental details is key for any procurement specialist in the pharmaceutical industry.

When considering the purchase of Macitentan intermediates, factors such as supplier reliability, product specifications, and market price are paramount. NINGBO INNO PHARMCHEM CO.,LTD. is a trusted supplier that understands the stringent requirements of pharmaceutical manufacturing. We ensure that our Potassium N-Propylsulfamide is handled and stored under optimal conditions to maintain its efficacy. Whether you are looking for specific quantities or require detailed technical data on the Macitentan synthesis reagent CAS 1393813-41-6, our team is equipped to assist.

The importance of this intermediate extends beyond its chemical properties; it directly contributes to the availability of treatments for patients suffering from pulmonary arterial hypertension. By providing a stable and high-quality supply of Potassium N-Propylsulfamide, NINGBO INNO PHARMCHEM CO.,LTD. plays a supportive role in the global healthcare ecosystem. We encourage potential partners and clients to reach out for detailed quotations and to learn more about how we can meet their specific needs for this critical pharmaceutical intermediate.